Dr. Cassie Kline, MD, MAS

PNOC Principal Investigator, Co-Project Leader, and Director of Data Quality and Integration

Dr. Cassie Kline is a pediatric neuro-oncologist at the Children’s Hospital of Philadelphia (CHOP) and an Assistant Professor of Pediatrics at the University of Pennsylvania Perelman School of Medicine. Her work centers on developing and implementing clinical trials for children and adolescents with brain tumors, particularly those with high-grade gliomas and medulloblastomas. As a PNOC project lead, Dr. Kline contributes to advancing precision-based and biology-driven therapies while ensuring equitable access to innovative treatments worldwide.

Education

Education

  • B.A., Biology, University of Virginia

  • M.D., University of California, San Diego

  • Internship and Residency, Pediatrics, Children’s Hospital of Philadelphia

  • Fellowship, Pediatric Hematology/Oncology, University of California, San Francisco

  • M.A.S., Clinical Research, University of California, San Francisco

Certifications

Certifications

  • American Board of Pediatrics, Pediatrics

  • American Board of Pediatrics, Pediatric Hematology/Oncology

Awards

Awards & Recognition

  • Cannonball Kids’ Cancer Young Investigator Award

  • UCSF Clinical and Translational Science Institute Career Development Award

  • UCSF School of Medicine John A. Watson Faculty Scholar

  • Children’s Brain Tumor Foundation, Pioneer Award for Pediatric Oncology

Research & Publications

Selected Research & Clinical Publications

  • Kline C, Wright K, Chi S, et al. Growth recovery in patients with BRAF-altered pediatric low-grade glioma following treatment with tovorafenib, Neuro-Oncology Pediatrics, Volume 2, Issue 2, April 2026, wuag021, Available from: https://doi.org/10.1093/neuped/wuag021

  • Kline C, Rokita JL, Mueller S, et al. Genetic ancestry superpopulations show distinct prevalence and outcomes across pediatric central nervous system tumors from the Pediatric Brain Tumor Atlas and Pediatric Neuro-Oncology Consortium, Neuro-Oncology, Volume 27, Issue 5, May 2025, Pages 1356–1371, Available from: https://doi.org/10.1093/neuonc/noaf017

  • Yu B, Kline C, Hoare O, et al. Measles oncolytic virus as an immunotherapy for recurrent/refractory pediatric medulloblastoma and atypical teratoid/rhabdoid tumor: Results from PNOC005. Clinical Cancer Research. 2025;31(16):3463–3475. doi:10.1158/1078-0432.CCR-24-3721. Available from: https://pubmed.ncbi.nlm.nih.gov/40540301/

  • Kline C, Jain P, Kilburn L, et al. Upfront biology-guided therapy in diffuse intrinsic pontine glioma: Therapeutic, molecular, and biomarker outcomes from PNOC003. Clinical Cancer Research. 2022;28(18):3965–3978. doi:10.1158/1078-0432.CCR-22-0803. Available from: https://pubmed.ncbi.nlm.nih.gov/35852795/

  • Kline C, Felton E, Allen IE, Tahir P, Mueller S. Survival outcomes in pediatric recurrent high-grade glioma: Results of a 20-year systematic review and meta-analysis. Journal of Neuro-Oncology. 2018;137(1):103–110. doi:10.1007/s11060-017-2701-8. Available from: https://pubmed.ncbi.nlm.nih.gov/29204840/

For a complete list of published work:

https://www.ncbi.nlm.nih.gov/myncbi/1diWyoj5phW53/bibliography/public/